Following a recommendation from the European Medicines Agency, the huge pharmaceutical firm Sanofi-Aventis has halted the sale of the anti-obesity drug Acomplia in the EU. Acomplia joins An ever growing list of approved drugs that are found to be high risk after approval

“The risks of taking Acomplia are now greater than the benefits that the drug can bring the patient according to its current guidelines,” the company said, citing the EMEA.

“Sanofi-aventis will comply with the European Authorities request to temporarily suspend the marketing authorisation of Acomplia in obese and overweight patients and will make every effort to actively support patients and Health Care Professionals this process.” said a company statement.

The drug is marketed in 18 EU countries and is used by an estimated 700,000 patients, according to company statements.

Source
Sanofi-Aventis